Balance Sheet

Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Apyx Medical (APYX) Long-Term Debt Issuances (2023)

Apyx Medical filings provide 1 years of Long-Term Debt Issuances readings, the most recent being $34.2 million for Q4 2023.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $34.2 million in Q4 2023 year-over-year; TTM through Sep 2024 was $34.2 million, a 268.02% increase, with the full-year FY2023 number at $43.5 million, changed N/A from a year prior.
Long-Term Debt Issuances hit $34.2 million in Q4 2023 for Apyx Medical, up from $9.3 million in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $34.2 million in Q4 2023 to a low of $9.3 million in Q1 2023.